Srs Pharmaceuticals Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 26-06-2024
- Paid Up Capital ₹ 5.00 Cr
as on 26-06-2024
- Company Age 23 YEARS, 6 MONTHS
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.40 Cr
as on 26-06-2024
- Satisfied Charges ₹ 0.60 Cr
as on 26-06-2024
- Revenue 295.17%
FY 2022
- Profit 3137.16%
FY 2022
- Ebitda 17.44%
FY 2022
- Net Worth 247.61%
FY 2022
- Total Assets 131.71%
FY 2022
About Srs Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹19.40 Cr. The company has closed loans amounting to ₹6.00 M, as per Ministry of Corporate Affairs (MCA) records.
Suchet Rastogi and Sangeeta Gamre serve as directors at the Company.
- CIN/LLPIN
U24239MH2001PTC131384
- Company No.
131384
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Mar 2001
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Srs Pharmaceuticals?
Board Members(2)
Financial Performance and Corporate Structure Insights of Srs Pharmaceuticals.
Srs Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 295.17% increase. The company also saw a substantial improvement in profitability, with a 3137.16% increase in profit. The company's net worth Soared by an impressive increase of 247.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| FY 2022 | FY 2021 | FY 2020 | FY 2019 | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Srs Pharmaceuticals?
In 2022, Srs Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
19 years 7 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Standard Chartered Bank Creation Date: 16 Sep 2015 | ₹1.50 M | Open |
Standard Chartered Bank Creation Date: 15 Dec 2009 | ₹8.00 Cr | Open |
Standard Chartered Bank Creation Date: 06 Jan 2005 | ₹11.25 Cr | Open |
How Many Employees Work at Srs Pharmaceuticals?
Srs Pharmaceuticals has a workforce of 87 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Srs Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Srs Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
